Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review

Table 1

Quality assessment of the included studies.

Criteria	Studies
	Della-Torre et.al.	Montesarchio et.al.	Benucci et.al.	Lescure et.al.	Gremese et.al.
Clarity of the study objectives	Yes	Yes	Yes	Yes	Yes
Whether the study period (start date and end date) was stated clearly or not	Yes	Yes	Yes	Yes	Yes
Whether the description of the patient selection criteria was clear or not	Yes	Yes	No	Yes	Yes
The stated sarilumab treatment method and dose	Yes	Yes	Yes	Yes	Yes
Study was conducted in multicenter or not	No	No	No	Yes	No
Whether the baseline equivalence groups were clearly considered or not	Yes	No	No	Yes	Yes
The definition of the primary outcome (PaO2/FiO2 ratio or overall mortality or ventilation requirement) prior to the study	Yes	Yes	No	Yes	Yes
If the follow-up period was long enough (at least two months)	No	No	No	Yes	No
Whether a clear hazard ratio (HR) with 95% confidence intervals (95% CI) was stated or not	No	No	No	Yes	No
The limitations of each study were considered	Yes	Yes	No	Yes	Yes
Overall score	7	6	3	10	7

Mean: 6.6.